Xenetic Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M |
| Research and development | $3.1M | $3.3M | $3.5M | $4.8M | $3.2M |
| Operating expenses | $5.8M | $6.7M | $7.1M | $8.4M | $6.9M |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | -$5.7M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M |
| Balance Sheet | |||||
| Current assets | $8.0M | $6.6M | $9.6M | $13.7M | $18.7M |
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M |
| Current liabilities | $968,025 | $894,263 | $809,585 | $1.1M | $1.4M |
| Total liabilities | $968,025 | $894,263 | $809,585 | $1.1M | $1.4M |
| Stockholders' equity | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$2.3M | -$2.8M | -$4.1M | -$4.6M | -$4.7M |
| Depreciation and amortization | — | — | — | $0 | $0 |
| Stock-based compensation | $64,787 | $171,814 | $283,085 | $511,480 | $410,437 |
| Impairments | — | $700,000 | $0 | $0 | $0 |
Shares outstanding 2.3M · Free float 71.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.